Roche Reports Long-Term Benefits of Venclexta/Venclyxto Based Combination for R/R Chronic Lymphocytic Leukemia
Shots:
- Five-year data from P-III MURANO trial shows sustained PFS with Venclexta/Venclyxto + MabThera/Rituxan vs BR in patients with r/r CLL
- The data showed a reduction in the risk of disease progression or death by 81%- m-OS (82.1% vs 62.2%)- patients who completed 2yrs. of treatment without the progressive disease- 63.8% had uMRD
- The P-III CLL14 study also confirms the potential of MRD measurements to predict future outcomes for people with prior untreated CLL who were treated with fixed-duration Venclexta/Venclyxto + Gazyva/Gazyvaro vs Gazyva/Gazyvaro + chlorambucil
Ref: Roche | Image: Roche
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com